Targeting Neuroinflammation via Purinergic P2 Receptors for Disease Modification in Drug-Refractory Epilepsy

Treatment of epilepsy remains a clinical challenge, with >30% of patients not responding to current antiseizure drugs (ASDs). Moreover, currently available ASDs are merely symptomatic without altering significantly the progression of the disease. Inflammation is increasingly recognized as playing...

Descripción completa

Detalles Bibliográficos
Autores principales: Engel, Tobias, Smith, Jonathon, Alves, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298823/
https://www.ncbi.nlm.nih.gov/pubmed/34305404
http://dx.doi.org/10.2147/JIR.S287740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298823/
https://www.ncbi.nlm.nih.gov/pubmed/34305404
http://dx.doi.org/10.2147/JIR.S287740

Ejemplares similares